Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + TACE + radiotherapy versus TACE + radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR1800017427Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Time to progression and Overall survival. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800017427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017427.